Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. The company is headquartered in Morrisville, North Carolina and currently employs 59 full-time employees. The company went IPO on 2018-07-26. The firm is focused on the development, manufacture, and commercialization of products that address unmet patient needs, with a focus on the treatment of pulmonary hypertension (PH). The firm operates, through its wholly owned subsidiaries, Liquidia Technologies, Inc., and Liquidia PAH, LLC. The company conducts research, development, and manufacturing of products by applying its expertise in cardiopulmonary diseases and its PRINT technology, a particle engineering platform that enables the production of uniform drug particles designed to improve the safety, efficacy, and performance of a range of therapies. Its lead product candidate is YUTREPIA for the treatment of pulmonary arterial hypertension (PAH). YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, low resistance dry-powder inhaler (DPI).